This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Three Reasons to Retain Accuray (ARAY) Stock in Your Portfolio
by Zacks Equity Research
The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.
Accuray (ARAY) Q2 Earnings Lag Estimates, Gross Margin Contracts
by Zacks Equity Research
Despite robust Services revenues, Accuray (ARAY) reports dismal second-quarter fiscal 2024 results.
Accuray (ARAY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
The headline numbers for Accuray (ARAY) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Unveiling Accuray (ARAY) Q2 Outlook: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Accuray (ARAY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Medical Product Stocks' Q4 Earnings Due on Jan 30: SYK & More
by Indrajit Bandyopadhyay
Fourth-quarter results of Medical Product companies are likely to reflect a year-over-year improvement in revenues. Let's see how SYK, COR and ARAY fare this time around.
Accuray's (ARAY) CyberKnife S7 to Enhance Radiation Treatment
by Zacks Equity Research
Accuray's (ARAY) latest generation CyberKnife S7 System is expected to boost the cancer treatment capabilities of the Providence Swedish Radiosurgery Center.
Strength Seen in PROCEPT BioRobotics Corporation (PRCT): Can Its 15.1% Jump Turn into More Strength?
by Zacks Equity Research
PROCEPT BioRobotics Corporation (PRCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Here's Why You Should Retain Accuray (ARAY) Stock for Now
by Zacks Equity Research
The continued solid demand for Accuray's (ARAY) products raises optimism about the stock.
Accuray (ARAY) Launches VitalHold in Japan for Use With Radixact
by Zacks Equity Research
Accuray's (ARAY) VitalHold is likely to transform breast cancer treatment in Japan by integrating SGRT for precise radiotherapy. It may become a game-changer for patients and medical staff.
Accuray (ARAY) Q1 Earnings In-Line With Estimates, Revenues Top
by Zacks Equity Research
Accuray (ARAY) reports a solid fiscal first quarter top line on the back of robust Product revenues.
Compared to Estimates, Accuray (ARAY) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Accuray (ARAY) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Accuray's (ARAY) Tomo C Radiation System Gets Approval in China
by Zacks Equity Research
Accuray's (ARAY) Tomo C radiation therapy system will enable medical care teams to provide personalized and highly precise treatments.
Accuray's (ARAY) New Offering to Boost Radiation Treatment Plans
by Zacks Equity Research
Accuray's (ARAY) latest offering is likely to improve radiation treatment.
Why Is Accuray (ARAY) Down 15.2% Since Last Earnings Report?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Accuray's (ARAY) Treatment Options to be Boosted Post FDA's Nod
by Zacks Equity Research
Accuray's (ARAY) latest regulatory approval is likely to improve breast cancer treatment.
New Strong Sell Stocks for August 11th
by Zacks Equity Research
NGLOY, ARAY and BANR have been added to the Zacks Rank #5 (Strong Sell) List on August 11, 2023.
Accuray (ARAY) Q4 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Accuray (ARAY) reports a solid fiscal fourth quarter top line on the back of robust segmental performances.
Accuray (ARAY) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Accuray (ARAY) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
AxoGen (AXGN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
AxoGen (AXGN) delivered earnings and revenue surprises of 80% and 3.16%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Teleflex (TFX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Teleflex (TFX) delivered earnings and revenue surprises of 6.23% and 1.90%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Cognizant (CTSH) Partners With Accuray to Improve Healthcare
by Zacks Equity Research
Cognizant's (CTSH) partnership agreement will enable Accuray to streamline and drive operational changes to improve patient care.
Accuray (ARAY) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Accuray's (ARAY) solid product portfolio.
Accuray (ARAY) Q3 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Accuray (ARAY) reports a solid fiscal third-quarter top line on the back of robust segmental performances.
Accuray (ARAY) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Accuray (ARAY) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Accuray (ARAY) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of 200% and 6.43%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?